Market Overview

UPDATE: Morgan Stanley Reiterates on IHS Following Meetings with Management

Related IHS
Analysts At BMO Capital Give Investors Their Picks In 4 Sectors
IHS Says Next Healthcare Treatment Wave Breakthroughs Coincides With Cost restraint In Western Europe

In a report published Tuesday, Morgan Stanley analyst Suzanne E. Stein reiterated an Equal-Weight rating on IHS (NYSE: IHS), but removed the $114.00 price target.

In the report, Morgan Stanley noted, “We remain Equal-weight on IHS shares given current valuation and challenges in accelerating top line growth and expanding margins. However, if recent investments translate into high single digit organic revenue growth and >100 bps of annual margin expansion, we believe the stock will seek higher levels. We look for an inflection point in performance that gives us more confidence that this transformation is underway.”

IHS closed on Monday at $118.98.

Latest Ratings for IHS

Mar 2016SunTrust Robinson HumphreyDowngradesBuyNeutral
Mar 2016Cantor FitzgeraldMaintainsHold
Mar 2016BarclaysMaintainsEqual-weight

View More Analyst Ratings for IHS
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Suzanne E. SteinAnalyst Color Price Target Analyst Ratings


Related Articles (IHS)

View Comments and Join the Discussion!